Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

The attrition rate for anticancer drugs entering clinical trials is unacceptably high. For multiple myeloma (MM), we postulate that this is because of preclinical models that overemphasize the antiproliferative activity of drugs, and clinical trials performed in refractory end-stage patients. We val...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chesi, Marta, Matthews, Geoffrey M., Garbitt, Victoria M., Palmer, Stephen E., Shortt, Jake, Lefebure, Marcus, Stewart, A. Keith, Johnstone, Ricky W., Bergsagel, P. Leif
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2012
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3398763/
https://ncbi.nlm.nih.gov/pubmed/22451422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-02-412783
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados